US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

REIN THERAPEUTICS INC

1.95

-0.0500-2.50%

Post-market: 1.950.00000.00%17:04 EDT

Volume:22.53K

Turnover:43.71K

Market Cap:43.20M

PE:-0.68

High:1.99

Open:1.99

Low:1.91

Close:2.00

Loading ...

Overview Company News Filings

BRIEF-Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf

Rein Therapeutics Announces First Patient Dosed in Renew Phase 2 Trial of Lti-03 in Patients With Ipf

THOMSON REUTERS

Rein Therapeutics Inc: Topline Interim Data From Renew Is Expected in First Half of 2026

THOMSON REUTERS

Rein Therapeutics : Sales Agreement Prospectus Covering Offering of up to $15.8 Mln of Common Stock

THOMSON REUTERS

Rein Therapeutics Inc Files for Mixed Shelf of up to $150 Mln – SEC Filing

THOMSON REUTERS

Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Rein Therapeutics Reports Q1 2025 Financial Results: Cash Position Declines, R&D and G&A Expenses Decrease

Press Release: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Rein Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Rein Therapeutics Announces Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis with Advanced AI Integration

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of Lti-03 in Patients With Ipf

THOMSON REUTERS

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

BRIEF-Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory Diseases

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder Lti-03 for the Treatment of Respiratory Diseases

THOMSON REUTERS

Rein Therapeutics’ LTI-2355 peptide shows therapuetic potential in study

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Press Release: Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RNTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RNTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNTX\",,,,,undefined,":{"symbol":"RNTX","market":"US","secType":"STK","nameCN":"REIN THERAPEUTICS INC","latestPrice":1.95,"timestamp":1749153600000,"preClose":2,"halted":0,"volume":22531,"hourTrading":{"tag":"盘后","latestPrice":1.95,"preClose":1.95,"latestTime":"17:04 EDT","volume":20,"amount":38,"timestamp":1749157470687},"delay":0,"floatShares":18619085,"shares":22153736,"eps":-2.870855,"marketStatus":"Not Yet Opened","change":-0.05,"latestTime":"06-05 16:00:00 EDT","open":1.99,"high":1.9905,"low":1.91,"amount":43709.9327148,"amplitude":0.04025,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.870855,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749196800000},"marketStatusCode":0,"adr":0,"listingDate":1498708800000,"exchange":"NASDAQ","adjPreClose":2,"postHourTrading":{"tag":"盘后","latestPrice":1.95,"preClose":1.95,"latestTime":"17:04 EDT","volume":20,"amount":38,"timestamp":1749157470687},"volumeRatio":0.970244},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNTX\",,,,,undefined,":{"symbol":"RNTX","floatShares":18619085,"roa":"-21.14%","roe":"-86.78%","lyrEps":-3.505399,"volumeRatio":0.970244,"shares":22153736,"dividePrice":0,"high":1.9905,"amplitude":0.04025,"preClose":2,"low":1.91,"week52Low":1.35,"pbRate":"8.86","week52High":4.4,"institutionHeld":0,"latestPrice":1.95,"eps":-2.870855,"divideRate":0,"volume":22531,"delay":0,"ttmEps":-2.870855,"open":1.99,"prevYearClose":2.3,"prevWeekClose":1.95,"prevMonthClose":1.95,"prevQuarterClose":1.77,"fiveDayClose":1.94,"twentyDayClose":1.63,"sixtyDayClose":1.91},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RNTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538663944","title":"BRIEF-Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf","url":"https://stock-news.laohu8.com/highlight/detail?id=2538663944","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538663944?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:09","pubTimestamp":1748347767,"startTime":"0","endTime":"0","summary":"BRIEF-Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With IpfMay 27  - REIN THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN RENEW PHASE 2 TRIAL OF LTI-03 IN PATIENTS WITH IPFREIN THERAPEUTICS INC: TOPLINE INTERIM DATA FROM RENEW IS EXPECTED IN FIRST HALF OF 2026Source text: ID:nPn15f7lca ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUA8R8VNC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1261432733.SGD","BK4139","LU0477156953.USD","LU0130102774.USD","LU1201861165.SGD","LU0198837287.USD","IQV","BK4121","LU0648000940.SGD","LU0130103400.USD","LU0130518102.USD","LU1791710400.SGD","LU0528227936.USD","LU0882574055.USD","LU0130517989.USD","LU0980610538.SGD","LU1989764664.SGD","BK4585","LU1791710582.SGD","LU0648001328.SGD","LU1989764748.USD","LU0477156797.USD","LU1201861249.SGD","BK4530","BK4588","RNTX"],"gpt_icon":0},{"id":"2538684854","title":"Rein Therapeutics Announces First Patient Dosed in Renew Phase 2 Trial of Lti-03 in Patients With Ipf","url":"https://stock-news.laohu8.com/highlight/detail?id=2538684854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538684854?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:00","pubTimestamp":1748343603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUA8R8VNC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU0130103400.USD","LU1201861249.SGD","LU0648001328.SGD","LU1989764748.USD","LU0980610538.SGD","LU0528227936.USD","LU0648000940.SGD","LU1791710582.SGD","RNTX","LU0198837287.USD","LU1791710400.SGD","LU1989764664.SGD","LU0130517989.USD","IQV","BK4588","BK4585","LU0477156797.USD","LU0477156953.USD","BK4121","LU1261432733.SGD","LU0130102774.USD","LU0882574055.USD","LU0130518102.USD","LU1201861165.SGD","BK4530"],"gpt_icon":0},{"id":"2538463468","title":"Rein Therapeutics Inc: Topline Interim Data From Renew Is Expected in First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2538463468","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538463468?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:00","pubTimestamp":1748343603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUA8R8VNC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0130102774.USD","LU0477156953.USD","LU0648001328.SGD","LU0130517989.USD","LU1989764748.USD","BK4585","LU0528227936.USD","LU0198837287.USD","LU0130103400.USD","LU0980610538.SGD","LU1791710400.SGD","BK4121","LU1791710582.SGD","LU1201861249.SGD","BK4139","LU0882574055.USD","LU1261432733.SGD","LU1989764664.SGD","BK4530","RNTX","LU1201861165.SGD","LU0648000940.SGD","IQV","LU0477156797.USD","LU0130518102.USD","BK4588"],"gpt_icon":0},{"id":"2535318627","title":"Rein Therapeutics : Sales Agreement Prospectus Covering Offering of up to $15.8 Mln of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2535318627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535318627?lang=en_us&edition=fundamental","pubTime":"2025-05-16 21:24","pubTimestamp":1747401876,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nFWN3RO1SS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"gpt_icon":0},{"id":"2535318625","title":"Rein Therapeutics Inc Files for Mixed Shelf of up to $150 Mln – SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2535318625","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535318625?lang=en_us&edition=fundamental","pubTime":"2025-05-16 21:24","pubTimestamp":1747401876,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nFWN3RO1SS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"gpt_icon":0},{"id":"2535166351","title":"Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535166351","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535166351?lang=en_us&edition=fundamental","pubTime":"2025-05-16 16:03","pubTimestamp":1747382587,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryRein Therapeutics Inc RNTX.OQ reported a quarterly adjusted loss of 25 cents per share for the quarter ended Marc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nL8N3RO0EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX"],"gpt_icon":0},{"id":"2535870174","title":"Rein Therapeutics Reports Q1 2025 Financial Results: Cash Position Declines, R&D and G&A Expenses Decrease","url":"https://stock-news.laohu8.com/highlight/detail?id=2535870174","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535870174?lang=en_us&edition=fundamental","pubTime":"2025-05-16 04:15","pubTimestamp":1747340111,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on May 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDLbVnsHM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"gpt_icon":0},{"id":"2535108870","title":"Press Release: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535108870","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535108870?lang=en_us&edition=fundamental","pubTime":"2025-05-16 04:09","pubTimestamp":1747339740,"startTime":"0","endTime":"0","summary":"RENEW Phase 2 trial evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis  initiated with topline interim data expected in the first half of 2026. Two abstracts accepted to the American Thoracic Society  2025 International Conference. Cash runway extended following previously announced warrant transactions and private placement. \"Rein has completed a multitude of key accomplishments since the beginning of the year, and we are particularly excited to have initiated the Phase 2 RENEW trial of LTI-03 in patients with IPF,\" said Brian Windsor, Ph.D., President and Chief Executive Officer of Rein Therapeutics. \"We have taken several strategic steps to prepare for this trial. Our LTI-03 program continues to evolve as we entered into a collaboration with Qureight to bring cutting-edge technology to our imaging and data analysis and obtained patents covering our novel formulation and administration methods. We are committed to continuing this momentum of ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSD","LENZ","RNTX","BK4161","BK4539","ATS","BK4139","BK4007"],"gpt_icon":0},{"id":"2534667644","title":"Rein Therapeutics Inc  expected to post a loss of 24 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2534667644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534667644?lang=en_us&edition=fundamental","pubTime":"2025-05-10 05:46","pubTimestamp":1746827165,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc  expected to post a loss of24cents a share - Earnings Preview Rein Therapeutics Inc RNTX.OQ RNTX.O is expected to show no change in quarterly revenue when it reports  results on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nL8N3RH3HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX"],"gpt_icon":0},{"id":"2532075065","title":"Rein Therapeutics Announces Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis with Advanced AI Integration","url":"https://stock-news.laohu8.com/highlight/detail?id=2532075065","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532075065?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:01","pubTimestamp":1746097310,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. has announced a collaboration with Qureight Ltd to integrate deep-learning technology into their upcoming Phase 2 clinical trial of LTI-03, aimed at treating idiopathic pulmonary fibrosis . This partnership will leverage Qureight's advanced AI imaging platform to provide detailed insights into the effects of LTI-03 on lung structure and function. The Phase 2 trial will assess the safety, tolerability, and activity of LTI-03 across multiple biomarkers, as well as its potential for promoting healthy tissue regeneration. Rein Therapeutics previously reported positive results from their Phase 1b trial, showing promising trends in biomarker response. Further details about the Phase 2 trial design are expected to be announced soon.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDLc0nR6g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"gpt_icon":0},{"id":"2532078288","title":"Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of Lti-03 in Patients With Ipf","url":"https://stock-news.laohu8.com/highlight/detail?id=2532078288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532078288?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097212,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nTUA1CQSHH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"gpt_icon":0},{"id":"2532075868","title":"Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF","url":"https://stock-news.laohu8.com/highlight/detail?id=2532075868","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532075868?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, May 1, 2025 /PRNewswire/ -- Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, and Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, today announced a collaboration for the integration of Qureight's deep-learning platform into Rein's planned Phase 2 trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis .Dr. Muhunthan Thillai, Chief Executive Officer of Qureight, said, \"We're delighted that our core platform and AI technology will be supporting Rein Therapeutics in advancing its treatment, LTI-03, for patients with IPF. Our AI tools will provide precise, quantitative insights into","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-qureight-ltd-announce-110000614.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-qureight-ltd-announce-110000614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSD","RNTX","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2530472503","title":"Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2530472503","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530472503?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:00","pubTimestamp":1745838000,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, April 28, 2025 /PRNewswire/ --Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications,today announced that an abstract has been accepted at the American Thoracic Society  2025 International Conference taking place May 18-21, 2025 in San Francisco, CA.Details of the poster presentation are as follows:. Presentation Title: Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides  in Three Dimensional  Alveolospheres from IPF and Normal Donor Lung Samples Poster #: P1463Session: B75 Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and FibrosisDate & Time: Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET. Rein Investor Relations & Media Contact:Argot Partnersrein@argotpartners.com 212-600-1902","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-announces-abstract-accepted-110000640.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-announces-abstract-accepted-110000640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","LENZ","BK4107","CSD","RNTX","BK4117","BK4139","BK4161","BK4007","ATS"],"gpt_icon":0},{"id":"2529550541","title":"BRIEF-Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2529550541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529550541?lang=en_us&edition=fundamental","pubTime":"2025-04-23 19:05","pubTimestamp":1745406317,"startTime":"0","endTime":"0","summary":"BRIEF-Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory DiseasesApril 23 (Reuters) - Rein Therapeutics I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA9V95FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"gpt_icon":0},{"id":"2529650562","title":"Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder Lti-03 for the Treatment of Respiratory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2529650562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529650562?lang=en_us&edition=fundamental","pubTime":"2025-04-23 19:00","pubTimestamp":1745406010,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA9V95FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"gpt_icon":0},{"id":"2527491244","title":"Rein Therapeutics’ LTI-2355 peptide shows therapuetic potential in study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527491244","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527491244?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:11","pubTimestamp":1744715464,"startTime":"0","endTime":"0","summary":"Rein Therapeutics (RNTX) announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmon...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-lti-2355-peptide-shows-therapuetic-potential-in-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-lti-2355-peptide-shows-therapuetic-potential-in-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","RNTX","BK4139"],"gpt_icon":0},{"id":"2527991034","title":"Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F","url":"https://stock-news.laohu8.com/highlight/detail?id=2527991034","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527991034?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"Manuscript highlights the effects of caveolin scaffolding domain peptide LTI-2355 on myeloid cell activity in Idiopathic Pulmonary Fibrosis  and Post-Acute Sequelae of COVID Fibrosis . AUSTIN, Texas, April 15, 2025 /PRNewswire/ --Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmonary Fibrosis  and Post-Acute Sequelae of COVID Fibrosis  in the peer-reviewed journal, Biomedicines.Rein Therapeuticsis a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-announces-publication-biomedicines-110000178.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-announces-publication-biomedicines-110000178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","BK4007","CSD","RNTX"],"gpt_icon":0},{"id":"2525076443","title":"Press Release: Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2525076443","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525076443?lang=en_us&edition=fundamental","pubTime":"2025-04-08 04:17","pubTimestamp":1744057020,"startTime":"0","endTime":"0","summary":"Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary fibrosis  in the first half of 2025. Positive topline results from Cohort 2  of the Phase 1b clinical trial of LTI-03 in IPF patients demonstrated dose dependent effects in five biomarkers evaluated, with four biomarkers achieving statistical significance in the combined Cohort 1 and Cohort 2 data set. AUSTIN, Texas, April 7, 2025 /PRNewswire/ -- Rein Therapeutics, Inc. , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update.and Phase 1b data for low dose LTI-03 , reinforcing the","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","RNTX","BK4007","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RNTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"RNTX","fiscalQuarterEnding":"2025/03","expectedEps":-0.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-04-07","symbol":"RNTX","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743998400000,"reportTimeType":"post","actualEps":-0.26},{"market":"US","date":"2024-11-14","symbol":"RNTX","fiscalQuarterEnding":"2024/09","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2024-08-14","symbol":"RNTX","fiscalQuarterEnding":"2024/06","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.45},{"market":"US","date":"2024-05-15","symbol":"RNTX","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RNTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RNTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1717214400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RNTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RNTX","date":"2025-06-04","current":-0.730371,"percent":0.649485,"low":-2.000549,"twenty":-1.569319,"median":-1.348518,"eighty":-0.632321,"high":-0.478916,"avg":-1.172152,"sd":0.460012,"marketCap":44750546},"quantilePoints":[{"date":"2025-01-17","current":-1.459659,"twenty":-1.48337,"median":-1.467068,"eighty":-1.447804,"marketCap":42681903},{"date":"2025-01-24","current":-1.630077,"twenty":-1.576729,"median":-1.478183,"eighty":-1.446322,"marketCap":47665070},{"date":"2025-01-31","current":-1.467069,"twenty":-1.741219,"median":-1.496707,"eighty":-1.462623,"marketCap":42898563},{"date":"2025-02-07","current":-1.704171,"twenty":-1.704171,"median":-1.526344,"eighty":-1.459659,"marketCap":49831664},{"date":"2025-02-14","current":-1.741218,"twenty":-1.704171,"median":-1.578211,"eighty":-1.462623,"marketCap":50914961},{"date":"2025-02-21","current":-1.98573,"twenty":-1.794566,"median":-1.630077,"eighty":-1.468551,"marketCap":58064721},{"date":"2025-02-28","current":-1.533754,"twenty":-1.79753,"median":-1.630077,"eighty":-1.47596,"marketCap":44848497},{"date":"2025-03-07","current":-1.467069,"twenty":-1.753073,"median":-1.607848,"eighty":-1.468551,"marketCap":42898563},{"date":"2025-03-14","current":-1.496707,"twenty":-1.741218,"median":-1.552277,"eighty":-1.467069,"marketCap":43765200},{"date":"2025-03-21","current":-1.430022,"twenty":-1.733809,"median":-1.518935,"eighty":-1.461141,"marketCap":41815266},{"date":"2025-03-28","current":-1.311471,"twenty":-1.704171,"median":-1.507821,"eighty":-1.431504,"marketCap":38348715},{"date":"2025-04-04","current":-1.259605,"twenty":-1.704171,"median":-1.496707,"eighty":-1.416685,"marketCap":36832099},{"date":"2025-04-11","current":-0.545587,"twenty":-1.696762,"median":-1.481888,"eighty":-1.32629,"marketCap":34308123},{"date":"2025-04-17","current":-0.577063,"twenty":-1.667124,"median":-1.474478,"eighty":-1.296652,"marketCap":36287438},{"date":"2025-04-25","current":-0.640015,"twenty":-1.630077,"median":-1.467069,"eighty":-1.259605,"marketCap":40246068},{"date":"2025-05-02","current":-0.573565,"twenty":-1.630077,"median":-1.459659,"eighty":-0.64701,"marketCap":36067514},{"date":"2025-05-09","current":-0.601544,"twenty":-1.630077,"median":-1.437431,"eighty":-0.622528,"marketCap":37826905},{"date":"2025-05-16","current":-0.825375,"twenty":-1.622667,"median":-1.430022,"eighty":-0.622528,"marketCap":51902033},{"date":"2025-05-23","current":-0.696336,"twenty":-1.607848,"median":-1.415203,"eighty":-0.629523,"marketCap":42665230},{"date":"2025-05-30","current":-0.696336,"twenty":-1.584138,"median":-1.407793,"eighty":-0.629523,"marketCap":42665230},{"date":"2025-06-04","current":-0.730371,"twenty":-1.569319,"median":-1.348518,"eighty":-0.632321,"marketCap":44750546}],"updateTime":1749174122287}}}